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Abstract: 
NS5 methyltransferase (Mtase) has a crucial role in the replication of dengue virus. There are two active sites on NS5 Mtase i.e., 
SAM and RNA-cap binding sites. Inhibition of the NS5 Mtase activity is expected to prevent the propagation of dengue virus. This 
study was conducted to design cyclic peptide ligands as enzyme inhibitors of dengue virus NS5 Mtase through computational 
approach. Cyclopentapeptides were designed as ligand of SAM binding site as much as 1635 and 736 cyclopentpeptides were 
designed as ligand of RNA-cap binding site. Interaction between ligand and NS5 Mtase has been conducted on the Docking 
simulation. The result shows that cyclopentapeptide CTWYC was the best peptide candidate on SAM binding site, with estimated 
free binding energy -30.72 kca/mol. Cyclopentapeptide CYEFC was the best peptide on RNA-cap binding site with estimated free 
binding energy -22.89 kcal/mol. Both peptides did not have tendency toward toxicity properties. So it is expected that both 
CTWYC and CYEFC ligands could be used as a potential antiviral drug candidates, which can inhibit the SAM and RNA-cap 
binding sites of dengue virus NS5 Mtase. 
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Background: 
Dengue fever is a serious threat to global health issues. 
Geographic distribution of this disease has undergone 
tremendous expansion over the last 30 years. Approximately 
100 countries are endemic for dengue fever and 40% of the 
world's population or about 2.5 billion people in the tropical 
and sub-tropics have an increased risk of catching the disease. 
More than 50 million of low-grade fever infections with 400,000 
cases of dengue hemorrhagic fever are reported annually, 
which has caused many deaths of children in several countries 
in the Asian [1]. 
 
Dengue virus has four serotypes i.e., DENV-1, DENV-2, DENV-
3, and DENV-4. The classification is based on the type of 
antibodies produced in the human body after infection. These 
four serotypes had the same morphology and genome but show 
d i f f e r e n t  a n t i g e n s  s o  t h a t  a  p e r s o n  c a n  b e  i n f e c t e d  w i t h  t h i s  
virus more than once in the absence of complete cross-
protection [2]. 
 
Nonstructural (NS) enzyme such as NS3 protease with NS2B 
cofactor, NS3 helicase/nucleoside triposfatase (NTPase)/ RNA 
5 'triposfatase (RTPase), NS5 methyltransferase (Mtase), and 
NS5 RNA-dependent RNA polymerase (RdRp) were known to 
have an important role in the replication of dengue virus [3]. 
Currently, NS3 and NS5 of dengue virus enzyme are the most 
understood mechanism, making these enzyme as an ideal target 
for antiviral manufacture of dengue virus [4].  
 
Several studies related to inhibition of the enzyme which is a 
potential target in the dengue virus have been carried out. 
Tambunan  et al.,  [5] designed cyclic peptides CKRKC as BIOINFORMATION  open access 
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potential inhibitors of NS2B-NS3 protease. Tambunan et al., [6] 
also designed of 49 cyclic peptides based on amino acid that 
could be recognized by the active site of NS2-NS3 protease and 
generating the best ligand CRKRC.  Podvinec et al., [7] used the 
S-Adenosil-homocysteine (SAH), triphosphate ribavirin, and 
sinefungin as analogues inhibitors of the NS5 
methyltransferase. The result showed that SAH has stability 
issues and indicate the nature of toxicity, ribavirin has a low 
activity, and sinefungin has low specificity and problems of 
nephrotoxicity.  Ribavirin triphosphate (RTP) and RTP-
analogues were designed as potential antiviral NS5 
methyltransferase [8]. Lim et al., [9] discovered several potential 
compounds that are active against dengue virus NS5 
methyltransferase through virtual screening using structure-
based and ligand-based methods. 
 
NS5 methyltransferase has two ties sides that are connected by 
a Y-shaped slit. The first binding site is the SAM (methyl donor) 
binding site and the second is the RNA-cap binding site that 
likely shallow and smaller in size [10]. This enzyme has two 
methylation processes, first step movement of a methyl group 
to the SAM binding site and then transfer the methyl group to 
the guanine bases of RNA. Although NS5 methyltransferase has 
two methylation processes, these are occurring at the same 
place [11]. RNA substrate is expected to change positions in 
order to receive the methyl group on the SAM binding site [12]. 
 
Currently, research on peptides for drug design and discovery 
are the most promising fields in the development of new drugs. 
More than 140 peptides were used as drugs and more than 400 
peptides have entered on preclinical phase with average growth 
of more than 15% in a year [13]. This study was conducted to 
design cyclic peptide for two binding pocket of dengue virus 
NS5 methyltransferase, so it could be used as an inhibitor of 
dengue virus NS5 methyltransferase. 
 
Methodology: 
Ligands design and preparation 
Determination of amino acid sequence was based on natural 
substrate NS5 methyltransferase that are regonized by the 
binding sites i.e., SAM binding site and RNA-cap binding site. 
Peptides were designed as cyclopentapeptides, which were 
joined by disulfide bonding at each terminal cystein and 
modeled into three-dimensional structure using ACDlabs. We 
designed cyclopentapeptides as ligand for SAM binding site 
and RNA-cap binding site. Preparation of cyclic peptides based 
on the polarity of amino acid residues at the active sites of the 
SAM and RNA-cap. Cyclopentapeptide optimization was 
carried out by choosing wash option, partial charge and energy 
minimization using MMFF94 forcefield, gas phase solvation 
and RMS gradient 0.001 kcal/ Å mol [14]. 
 
NS5 methyltransferase preparation 
Structure of NS5 methyltransferase with code 2P41 was 
obtained from PDB and was loaded into Molecular Operating 
Environment (MOE) 2008.10. The enzyme structure was 
repaired and optimized using the protonate3D option in MOE 
[15]. Hydrogen atoms were added by choosing partial charge 
option. Energy minimization was performed by employing 
MMFF94x force field, gas phase solvation and RMS gradient 
0.05 kcal/ Å mol [14]. 
 
Molecular docking 
Molecular docking was performed by choosing Simulation-
dock option in MOE. Triangle matcher was generated as 
placement method. Triangle matcher method generates poses in 
a systematic manner and more accurate way than the alpha 
triangle method by aligning the ligand triplet of atoms with the 
triplet of alpha spheres in cavities of tight atomic packing [15]. 
A London dG scoring function was used to rank candidate 
poses. Forcefield was used in refinement and repetition was set 
to 100 with only one best pose to be retained. 
 
Toxicity prediction 
Analysis of toxicity of the ligands were carried out on the best 
ligand docking results. Parameters that will be seen from the 
nature of the ligand are carcinogenicity and mutagenicity. The 
analysis was performed using software ToxTree v2.1.0 and 
Osiris Property Explorer. Toxicology analysis based on the rule 
Benigni / Bossa rulebase for mutagenicity and carcinogenicity 
developed by Romualdo Benigni and Cecilia Bossa from the 
Instituto Superiore in Sanita, Rome, Italy, and approved by the 
European Chemical Bureau, Institute for Health and 
Consumers Protection, European Commission-Joint Research 
Centre (JRC) in 2008.. 
 
Disscussion: 
Ligands Screening 
The inhibitors cyclopentapeptide designed was consisted of two 
cysteines at the end and three other amino acids are combined 
in the middle. Preparation of cyclic peptides by S-S bridge is 
intended to improve the stability of the ligand [16].  From 
combination of 20 amino acids based on polar and nonpolar, we 
obtained 1635 cyclopentapeptides as ligand for SAM binding 
site and 736 cyclopentapeptides for RNA-cap binding site. 
Screening of all ligands resulted in obtaining eight best ligands. 
The eight cyclopentapeptides that we designed are illustrated in 
(Figure 1). Four cyclopentapeptides as the best inhibitor on the 
SAM active side and four cyclopentapeptides on the RNA-cap 
pocket. Table 1 & 2 (see supplementary material) showed that 
CTWYC and CYEFC as the best inhibitor for SAM and RNA-
cap site respectively. 
 
 
Figure 1: Illustrates (2D) eight cyclopentapeptides by S-S 
bridge, (a) Four cyclopentapeptides as the best inhibitor for the 
SAM active side and (b) Four cyclopentapeptides for the RNA-
cap pocket. 
 
SAM Binding Site 
Residues that are on the SAM binding site includes Ser56, 
Lys61, Cys82, Gly86, Trp87, Thr104, Lys105, Asp131, Val132, BIOINFORMATION  open access 
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Phe133, Asp146, Ile147, Lys181, and Glu217. It had been 
reported that residues Lys61, Asp146, Lys181 and Glu217 are 
important on the SAM active site [17]. 
 
Result by screening of 1635 ligands was obtained CTWYC as 
the best inhibitor of the SAM site with binding free energy 
(∆Gbinding) of -30.72 kcal/mol. There are three polar interactions 
formed between CTWYC and SAM site (Figure 2), i.e., polar 
basic, polar acidic, and polar uncharged. Lys61, Lys105 and 
Lys181 are polar basic. The sidechain of Lys61 and Lys181 were 
interacted with CTWYC molecule by forming hydrogen bonds 
with the carboxyl site of cystein, and the backbond nitrogen of 
Lys105 was interacted by forming hydrogen bond with the 4–
OH site of tyrosine. Glu217 is polar acidic, the backbond oxygen 
of Glu217 was interacted with CTWYC molecule by forming 
hydrogen bond with amino site of cystein. Ser150 is polar 
uncharged, the backbond nitrogen of Ser150 was interacted by 
forming hydrogen bond with the OH sidechain of threonine. 
 
Binding free energy (∆Gbinding) of cyclic peptide CTWYC while 
compared with SAM and SAH standards, has a value of   
∆Gbinding  is much greater, it provides a sen se that strength of 
CTWYC to inhibit the SAM active site was better stable. pKi 
value or affinity of CTWYC also larger from the other.  
 
 
Figure 2: Interactions formed between CTWYC and SAM 
binding site. There are three polar interactions by forming 
hydrogen bonds between CTWYC and SAM binding site. 
 
RNA-cap Site 
Residues has a role important at the RNA-cap site are Lys14, 
Leu17, Asn18, Leu20, Phe25, Lys29, Ser150, and Ser151  [17]. 
CYEFC cyclic peptide is the best inhibitor of RNA-cap site with 
binding free energy (∆Gbinding) of -22.89 kcal/mol. This result 
was obtained by screening of 736 cyclic peptides. There are 
three polar interactions formed between CYEFC and RNA-cap 
site  (Figure 3), i.e., polar basic, polar acidic, and polar 
uncharged. Lys29 is polar basic; the sidechain of Lys29 was 
interacted with CYEFC molecule by forming hydrogen bonds 
with the OH carboxyl of glutamate sidechain. Glu149 is polar 
acidic, the sidechain of Glu149 was interacted by forming 
hydrogen bonds with amina site of cystein.  Asn18, Ser150, and 
Ser214 are polar uncharged. The backbond nitrogen of Asn18 
was interacted with CYEFC molecule by forming hydrogen 
bonds with 4-OH of tyrosine. Ser150 was interacted with 
CYEFC by forming two hydrogen bonds, from the backbond 
and the sidechain of Ser150. The backbond of Ser150 was 
performed hydrogen bonds with amine site of cystein and the 
sidechain of Ser150 was performed hydrogen bonds with 
oxygen carboxyl of cystein. Ser214 was interacted by 
performing hydrogen bonds with carboxyl sidechain of 
glutamic acid. 
 
Binding free energy (∆Gbinding) of cyclic peptide CYEFC while 
compared with RTP standards, has a value of ∆Gbinding is much 
greater, it provides a sense that strength of CTWYC to inhibit 
the RNA-cap site was better stable. pKi value or affinity of 
CYEFC also larger from the other but the value is below from 
the standard .  
 
 
Figure 3: Interactions formed between CYEFC and RNA-cap 
site. There are three polar interactions by forming hydrogen 
bonds between CYEFC and RNA-cap site. 
 
Toxicity Prediction 
Toxicological prediction using Toxtree, all the ligands for both 
of the targets SAM and RNA-cap sites did not have structural 
alerts (SAs) which are genotoxic and nongenotoxic properties. 
QSARs approach also showed that all ligands are not 
mutagenic or carcinogenic. The same results occured in the 
standard ligand RTP had no structural alerts (SAs) which are 
genotoxic and nongenotoxic. In other hand, standard ligand 
SAH was known to have structural alerts (SAs) which are 
nongenotoxic compounds and has potential as carcinogens. 
Predictions using the Osiris Property Explorer, SAM and SAH 
standards ligands have a higher tendency to mutagenic and 
effective reproductive properties, whereas the RTP standard 
ligand has no issues either on the mutagenic or tumorigenic 
properties, but has problems with the effective reproductive. 
All peptide ligands, for both targets did not have tendencies 
toward toxicity properties.  
 
Conclusion:  
We have performed several cyclic peptides as potential 
inhibitor of dengue virus NS5 Mtase through virtual screening 
using docking-based methods. These peptides were predicted 
to bind by forming hydrogen bonds to SAM and RNA-cap sites 
with higher binding free energy (∆Gbinding) than standards. 
CTWYC cyclic peptide is  the best inhibitor of the SAM site with 
binding free energy (∆Gbinding) of -30.72 kcal/mol. CYEFC cyclic 
peptide is the best inhibitor of RNA-cap site with binding free 
energy (∆Gbinding) of -22.89 kcal/mol. CTWYC and CYEFC did 
not have a tendency towards toxicity properties. CTWYC and 
CYEFC expected that it could be used as potential antiviral 
drug candidate, which can inhibit the SAM and RNA-cap 
binding sites of dengue virus NS5 Mtase. BIOINFORMATION  open access 
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 8(8): 348-352 (2012)  351   © 2012 Biomedical Informatics
 
Acknowledgment: 
This research is support by University of Indonesia (Riset 
Unggulan Universitas Indonesia tahap-1, 2012). The authors are 
grateful to Prof. T. Khayamian, Departement of Chemintry, 
Isfahan Technological University, Isfahan, Iran for his critical 
comments and excellent assistance in proof-reading the 
manuscript. 
 
References: 
[1]  Guglani L & Kabra SK, Dengue Bull. 2005  29: 58  
[2]  Whitehorn J & Farrar J, British Medical Bulletin. 2010 95: 161  
[3]  Kahn AM et al. PLoS Negl Trop Dis. 2008 2: 8 e272 [PMID: 
18698358] 
[4]  Noble CG et al. Antiviral Res. 2010 85: 3 [PMID: 20060421] 
[5]  Tambunan USF & Alamudi S, Bioinformation 2010 5: 6 
[PMID: 21364826] 
[6]  Tambunan USF et al. African Journal of Biotechnology. 2011 
10: 57  
[7]  Podvinec et al. J Med Chem. 2010 53: 4 [PMID: 20108931] 
[8]  Sivakumar D & T Sivaraman, Med Chem. 2011 7: 6 [PMID: 
22313305] 
[9]  Lim SV et al.  BMC Bioinformatics. 2011  12: 13 [PMID: 
22373153] 
[10] Lim SP et al. J Biol Chem. 2011 286: 8 [PMID: 21147775] 
[11] Courageot MP et al. J Virol. 2000 80: 3 [PMID: 10590151] 
[12] Lim SP et al. Antiviral Res. 2008 80: 3 [PMID: 18809436] 
[13] Huther A & U Dietrich,  AIDS Rev. 2007 9: 4 [PMID: 
18219364]  
[14] Manavalan  et al. BMC Struc Biol. 2010  10: 1 [PMID: 
20067617] 
[15] Feher M & CI William, J Chem Inf Model. 2009 49: 7 [PMID: 
19530660] 
[16] Hell AJ et al. Pharm Res. 2009 26: 9 [PMID: 19582551] 
[17] Benarroch D et al. J Biol Chem. 2004  279: 34 [PMID: 
15152003] 
 
 
 
Edited by P Kangueane 
Citation: Idrus et al. Bioinformation 8(8): 348-352 (2012) 
License statement: This is an open-access article, which permits unrestricted use, distribution, and reproduction in any medium, 
for non-commercial purposes, provided the original author and source are credited. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 BIOINFORMATION  open access 
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 8(8): 348-352 (2012)  352   © 2012 Biomedical Informatics
 
Supplementary material:  
 
Table 1: Data of binding free energy and inhibition constants in SAM binding site and RNA-cap sites 
Peptide  ΔGbinding(kcal/mol) pKi  Peptide  ΔGbinding (kkal/mol) pKi 
CTWYC -30,7216  13,687  CYEFC -22,8976  13,385 
CYWHC -29,9735  13,972  CYDFC -22,5276  11,667 
CYDHC -24,9373  15,175  CYQNC  -20,9224  11,176 
CTRYC -22,1155  11,787  CTNYC  -18,4686  9,361 
Standar SAM  -17,8521  11,298  Standar RTP  -14,4011  14,343 
Standar SAH   -15,1564  11,102       
 
Table 2: Ligands toxicity prediction of SAM and RNA-cap sites by using Toxtree software 
  SAM SAH CTWYC CYWHC CYDHC CTRYC   RTP  CYEFC CYDFC CYQNC CTNYC 
Structural alert 
for genotoxic 
carcinogenicity 
Yes  Yes  No No No No Structural alert 
for genotoxic 
carcinogenicity 
No No  No  No  No 
Structural alert 
for 
nongenotoxic 
carcinogenicity 
No  No  No No No No Structural alert 
for 
nongenotoxic 
carcinogenicity 
No No  No  No  No 
Potential 
carcinogen 
based on 
QSAR 
No  No  No No No No Potential 
carcinogen 
based on 
QSAR 
No No  No  No  No 
Potential 
S.typhimurium 
TA100 
mutagen based 
on QSAR 
No  No  No No No No Potential 
S.typhimurium 
TA100 mutagen 
based on 
QSAR 
No No  No  No  No 
Negative for 
genotoxic 
carcinogenicity 
No  No  Yes Yes Yes Yes Negative for 
genotoxic 
carcinogenicity 
Yes Yes  Yes  Yes  Yes 
Negative for 
nongenotoxic 
carcinogenicity 
Yes  Yes  Yes Yes Yes Yes Negative for 
nongenotoxic 
carcinogenicity 
Yes Yes  Yes  Yes  Yes 
 
Table 3:  Ligands toxicity prediction of SAM and RNA-cap sites by using Osiris Property Explorer 
  SAM  SAH  CTWYC CYWHC CYDHC CTRYC   RTP  CYEFC CYDFC CYQNC CYDHC 
Mutagenic  Yellow Yellow Green  Green  Green  Green  Mutagenic  Green Green Green  Green  Green 
Tumorigenic  Green Green Green  Green  Green  Green  Tumorigenic  Green Green Green  Green  Green 
Irritant  Green Green Green  Green  Green  Green  Irritant  Green Green Green  Green  Green 
Reproductive 
effective 
Yellow Yellow Green  Green  Green  Green  Reproductive 
effective 
Yellow Green  Green  Green  Green 
Druglikeness  -13,82 -13,57 -0,70  -0,09  -0,74  -0,77  Druglikeness  -27,98 0,20  0,31  -1,22  1,46 
Drug Score  0,25 0,27 0,38  0,40  0,38  0,38  Drug Score  0,32 0,47 0,45  0,36  0,56 
 